Akston Biosciences and Biolexis Collaborate to Launch a COVID-19 Vaccine in 130+ Countries

Covid-19 protein subunit vaccine – AKS-452

Transportable without cold-chain:

Shelf-stable for over six months at 25° Celsius (77° Fahrenheit)

Maintains potency for one month at 37° Celsius (99° Fahrenheit)

High volume, low cost manufacturing:

Uses established antibody production infrastructure

Single production line can make over one billion doses per year

Does not include mRNA technology, viral vectors, or a weakened SARS-CoV-2 virus

Focused presentation of Receptor Binding Domain (RBD)

Designed to preserve effectiveness against viral variants

Suitable for boosting immune response of those vaccinated or recovered from infection

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

Vaccine, October 29, 2021

Read More

News & Press


Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the... Read More

In the News

Easier-To-Produce Room Temperature Covid Shot Shows Promise In Early Clinical Trials

Forbes – February 2, 2022 – A protein-based Covid-19 vaccine by Akston Biosciences that can be stored at room temperature and efficiently manufactured using existing technology was well-tolerated and provoked an immune response... Read More

Akston Press

Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries

Beverly, Mass. – March 17, 2022 – Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, and Biolexis, a division of Stelis Biopharma Limited (Stelis)... Read More

See All News & Press

Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Akston has partnered with Biolexis Private Limited of the Strides Group to manufacture and commercialize AKS-452 (branded as AmbiVax-CTM) in India and over 130 countries in Asia, Latin America, and Africa. It has also partnered Dechra Pharmaceuticals PLC (DPH) to commercialize once-a-week canine and feline insulin therapies. It was founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc. (sold to Merck & Co.). Akston operates a GMP biologics manufacturing cleanroom facility and research laboratory at its Beverly, Mass. location.